1 |
Fernández-codina A, Orozco-gálvez O, Martínez-valle F. Therapeutic Options in IgG4-Related Disease. Curr Treat Options in Rheum 2020;6:191-204. [DOI: 10.1007/s40674-020-00147-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
2 |
Takanashi S, Akiyama M, Nishina N, Kaneko Y, Takeuchi T. Characteristics and prognosis of IgG4-related skin disease: A case report and systematic literature review. Autoimmun Rev 2021;20:102805. [PMID: 33727155 DOI: 10.1016/j.autrev.2021.102805] [Reference Citation Analysis]
|
3 |
Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease. BMJ 2020;369:m1067. [PMID: 32546500 DOI: 10.1136/bmj.m1067] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
|
4 |
Kim HJ, Lee S, Koo YJ, Kwon E, Kim HJ, Choi JY, Kim JS. Tacrolimus for Treating Orbital and Cranial Form of Idiopathic Inflammatory Pseudotumors. J Clin Neurol 2020;16:674-80. [PMID: 33029975 DOI: 10.3988/jcn.2020.16.4.674] [Reference Citation Analysis]
|
5 |
Tian M, Luan J, Jiao C, Chang Q, Kopp JB, Zhou H. Co-occurrence of IgA nephropathy and IgG4-Tubulointersitial nephritis effectively treated with tacrolimus: a case report. BMC Nephrol 2021;22:279. [PMID: 34384379 DOI: 10.1186/s12882-021-02477-w] [Reference Citation Analysis]
|